• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.

作者信息

Chiba K, Ishizaki T, Miura H, Minagawa K

出版信息

J Pediatr. 1980 Mar;96(3 Pt 1):479-84. doi: 10.1016/s0022-3476(80)80705-0.

DOI:10.1016/s0022-3476(80)80705-0
PMID:7359247
Abstract

Michaelis-Menten pharmacokinetics were evaluated for diphenylhydantoin given to 104 patients 0.5 to 16 years of age with seizures. A method for individualizing the dosage regimen of DPH for each patient was evaluated retrospectively. The Vmax was inversely related to age (r = 0.552, P less than 0.001) but there was no such relationship for Km. The individual pharmacokinetics were characteristic of that person and could be used to adjust dosage so that toxicity would be avoided. We present a nomogram for adjusting the dosage of DPH in the pediatric age groups.

摘要

相似文献

1
Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.
J Pediatr. 1980 Mar;96(3 Pt 1):479-84. doi: 10.1016/s0022-3476(80)80705-0.
2
Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient.
Folia Psychiatr Neurol Jpn. 1980;34(3):295. doi: 10.1111/j.1440-1819.1980.tb01538.x.
3
Apparent Michaelis-Menten kinetic parameters of phenytoin in pediatric patients.
Pediatr Pharmacol (New York). 1980;1(2):171-80.
4
Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
Ther Drug Monit. 1984;6(1):11-4.
5
Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.
Clin Pharmacokinet. 1983 Nov-Dec;8(6):545-9. doi: 10.2165/00003088-198308060-00006.
6
Phenytoin dosage requirements and pharmacokinetic variables.
Clin Pharm. 1983 May-Jun;2(3):253-7.
7
Phenytoin age-dose-concentration relationship in children.
Ther Drug Monit. 1994 Apr;16(2):145-50. doi: 10.1097/00007691-199404000-00006.
8
Diphenylhydantoin elimination kinetics in overdosed children.过量服药儿童中苯妥英的消除动力学
Clin Pharmacol Ther. 1975 Apr;17(4):481-91. doi: 10.1002/cpt1975174481.
9
Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
Clin Pharmacol Ther. 1977 Mar;21(3):294-300. doi: 10.1002/cpt1977213294.
10
Diphenylhydantoin: efficacy, toxicity, and dose-serum level relationships in children.
J Pediatr. 1972 Nov;81(5):995-1002. doi: 10.1016/s0022-3476(72)80561-4.

引用本文的文献

1
Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.环磷酰胺药代动力学候选基因与中危横纹肌肉瘤无事件生存的药物基因组学关联:来自儿童肿瘤组的报告。
Pediatr Blood Cancer. 2021 Nov;68(11):e29203. doi: 10.1002/pbc.29203. Epub 2021 Jul 10.
2
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.含富马酸替诺福韦二吡呋酯和阿扎那韦-利托那韦的抗逆转录病毒方案在青少年和年轻成人人类免疫缺陷病毒感染者中的药代动力学。
Antimicrob Agents Chemother. 2008 Feb;52(2):631-7. doi: 10.1128/AAC.00761-07. Epub 2007 Nov 19.
3
Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.代谢物生成动力学建模的经典米氏方程和系统理论方法
Eur J Drug Metab Pharmacokinet. 2004 Jul-Sep;29(3):205-14. doi: 10.1007/BF03190599.
4
Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.抗癫痫药物治疗的优化。血清药物浓度监测的重要性。
Clin Pharmacokinet. 1996 Aug;31(2):120-30. doi: 10.2165/00003088-199631020-00004.
5
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.抗癫痫药物在儿科患者中的临床药代动力学。第二部分。苯妥英、卡马西平、舒噻美、拉莫三嗪、氨己烯酸、奥卡西平和非氨酯。
Clin Pharmacokinet. 1995 Nov;29(5):341-69. doi: 10.2165/00003088-199529050-00004.
6
Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.孕期及哺乳期的抗惊厥药。经胎盘、母体及新生儿的药代动力学。
Clin Pharmacokinet. 1982 Nov-Dec;7(6):508-43. doi: 10.2165/00003088-198207060-00003.
7
Ethnic differences in drug metabolism.药物代谢中的种族差异。
Clin Pharmacokinet. 1982 Sep-Oct;7(5):373-400. doi: 10.2165/00003088-198207050-00001.
8
Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.
Clin Pharmacokinet. 1983 Nov-Dec;8(6):545-9. doi: 10.2165/00003088-198308060-00006.
9
Steady-state pharmacokinetics of phenytoin from routinely collected patient data.
Clin Pharmacokinet. 1983 Jul-Aug;8(4):355-64. doi: 10.2165/00003088-198308040-00006.
10
Anticonvulsants in the newborn period.新生儿期的抗惊厥药。
Indian J Pediatr. 1985 Sep-Oct;52(418):513-26. doi: 10.1007/BF02751028.